Skip to main content
Top
Published in: Diabetologia 8/2017

Open Access 01-08-2017 | Article

Antibodies to post-translationally modified insulin as a novel biomarker for prediction of type 1 diabetes in children

Authors: Rocky Strollo, Chiara Vinci, Nicola Napoli, Paolo Pozzilli, Johnny Ludvigsson, Ahuva Nissim

Published in: Diabetologia | Issue 8/2017

Login to get access

Abstract

Aims/hypothesis

We have shown that autoimmunity to insulin in type 1 diabetes may result from neoepitopes induced by oxidative post-translational modifications (oxPTM). Antibodies specific to oxPTM-insulin (oxPTM-INS-Ab) are present in most newly diagnosed individuals with type 1 diabetes and are more common than autoantibodies to native insulin. In this study, we investigated whether oxPTM-INS-Ab are present before clinical onset of type 1 diabetes, and evaluated the ability of oxPTM-INS-Ab to identify children progressing to type 1 diabetes.

Methods

We used serum samples collected longitudinally from the ‘All Babies in Southeast Sweden (ABIS)’ cohort tested for the gold standard islet autoantibodies to insulin (IAA), GAD (GADA), tyrosine phosphatase 2 (IA-2A) and zinc transporter 8 (ZnT8A). We studied 23 children who progressed to type 1 diabetes (progr-T1D) and 63 children who did not progress to type 1 diabetes (NP) after a median follow-up of 10.8 years (interquartile range 7.7–12.8). Of the latter group, 32 were positive for one or more islet autoantibodies (NP-AAB+). oxPTM-INS-Ab to insulin modified by OH or HOCl were measured by our developed ELISA platform.

Results

Antibodies to at least one oxPTM-INS were present in 91.3% of progr-T1D children. oxPTM-INS-Ab co-existed with GADA, IA-2A, IAA or ZnT8A in 65.2%, 56.5%, 38.9% and 33.3% progr-T1D children, respectively. In addition, oxPTM-INS-Ab were present in 17.4%, 26.1%, 38.9% and 41.6% of progr-T1D children who were negative for GADA, IA-2A, IAA and ZnT8A, respectively. OH-INS-Ab were more common in progr-T1D children than in NP-AAB+ children (82.6% vs 19%; p < 0.001) and allowed discrimination between progr-T1D and NP-AAB+ children with 74% sensitivity and 91% specificity. None of the NP-AAB children were positive for oxPTM-INS-Ab.

Conclusions/interpretation

oxPTM-INS-Ab are present before the clinical onset of type 1 diabetes and can identify children progressing to type 1 diabetes.
Literature
1.
go back to reference Knip M, Siljander H, Ilonen J, Simell O, Veijola R (2016) Role of humoral beta-cell autoimmunity in type 1 diabetes. Pediatr Diabetes 17(Suppl 22):17–24CrossRefPubMed Knip M, Siljander H, Ilonen J, Simell O, Veijola R (2016) Role of humoral beta-cell autoimmunity in type 1 diabetes. Pediatr Diabetes 17(Suppl 22):17–24CrossRefPubMed
2.
3.
go back to reference Babon JA, DeNicola ME, Blodgett DM et al (2016) Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nat Med 22:1482–1487CrossRefPubMedPubMedCentral Babon JA, DeNicola ME, Blodgett DM et al (2016) Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nat Med 22:1482–1487CrossRefPubMedPubMedCentral
4.
go back to reference Strollo R, Rizzo P, Spoletini M et al (2013) HLA-dependent autoantibodies against post-translationally modified collagen type II in type 1 diabetes mellitus. Diabetologia 56:563–572CrossRefPubMed Strollo R, Rizzo P, Spoletini M et al (2013) HLA-dependent autoantibodies against post-translationally modified collagen type II in type 1 diabetes mellitus. Diabetologia 56:563–572CrossRefPubMed
5.
go back to reference van Lummel M, Duinkerken G, van Veelen PA et al (2014) Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes 63:237–247CrossRefPubMed van Lummel M, Duinkerken G, van Veelen PA et al (2014) Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes 63:237–247CrossRefPubMed
6.
go back to reference Rondas D, Crevecoeur I, DʼHertog W et al (2015) Citrullinated glucose-regulated protein 78 is an autoantigen in type 1 diabetes. Diabetes 64:573–586CrossRefPubMed Rondas D, Crevecoeur I, DʼHertog W et al (2015) Citrullinated glucose-regulated protein 78 is an autoantigen in type 1 diabetes. Diabetes 64:573–586CrossRefPubMed
7.
go back to reference McGinty JW, Chow IT, Greenbaum C, Odegard J, Kwok WW, James EA (2014) Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes. Diabetes 63:3033–3040CrossRefPubMedPubMedCentral McGinty JW, Chow IT, Greenbaum C, Odegard J, Kwok WW, James EA (2014) Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes. Diabetes 63:3033–3040CrossRefPubMedPubMedCentral
8.
go back to reference Ryan BJ, Nissim A, Winyard PG (2014) Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases. Redox Biol 2:715–724CrossRefPubMedPubMedCentral Ryan BJ, Nissim A, Winyard PG (2014) Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases. Redox Biol 2:715–724CrossRefPubMedPubMedCentral
9.
go back to reference Strollo R, Ponchel F, Malmstrom V et al (2013) Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. Arthritis Rheum 65:1702–1712CrossRefPubMed Strollo R, Ponchel F, Malmstrom V et al (2013) Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. Arthritis Rheum 65:1702–1712CrossRefPubMed
10.
go back to reference Doyle HA, Mamula MJ (2012) Autoantigenesis: the evolution of protein modifications in autoimmune disease. Curr Opin Immunol 24:112–118CrossRefPubMed Doyle HA, Mamula MJ (2012) Autoantigenesis: the evolution of protein modifications in autoimmune disease. Curr Opin Immunol 24:112–118CrossRefPubMed
11.
go back to reference Strollo R, Vinci C, Arshad MH et al (2015) Antibodies to post-translationally modified insulin in type 1 diabetes. Diabetologia 58:2851–2860CrossRefPubMed Strollo R, Vinci C, Arshad MH et al (2015) Antibodies to post-translationally modified insulin in type 1 diabetes. Diabetologia 58:2851–2860CrossRefPubMed
12.
go back to reference Marra G, Cotroneo P, Pitocco D et al (2002) Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. Diabetes Care 25:370–375CrossRefPubMed Marra G, Cotroneo P, Pitocco D et al (2002) Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. Diabetes Care 25:370–375CrossRefPubMed
13.
go back to reference Matteucci E, Giampietro O (2000) Oxidative stress in families of type 1 diabetic patients. Diabetes Care 23:1182–1186CrossRefPubMed Matteucci E, Giampietro O (2000) Oxidative stress in families of type 1 diabetic patients. Diabetes Care 23:1182–1186CrossRefPubMed
14.
go back to reference Newsholme P, Rebelato E, Abdulkader F, Krause M, Carpinelli A, Curi R (2012) Reactive oxygen and nitrogen species generation, antioxidant defenses, and β-cell function: a critical role for amino acids. J Endocrinol 214:11–20CrossRefPubMed Newsholme P, Rebelato E, Abdulkader F, Krause M, Carpinelli A, Curi R (2012) Reactive oxygen and nitrogen species generation, antioxidant defenses, and β-cell function: a critical role for amino acids. J Endocrinol 214:11–20CrossRefPubMed
15.
go back to reference Ziegler AG, Rewers M, Simell O et al (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309:2473–2479CrossRefPubMedPubMedCentral Ziegler AG, Rewers M, Simell O et al (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309:2473–2479CrossRefPubMedPubMedCentral
17.
go back to reference Wenzlau JM, Juhl K, Yu L et al (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 104:17040–17045CrossRefPubMedPubMedCentral Wenzlau JM, Juhl K, Yu L et al (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 104:17040–17045CrossRefPubMedPubMedCentral
18.
go back to reference Ludvigsson J, Ludvigsson M, Sepa A (2001) Screening for prediabetes in the general child population: maternal attitude to participation. Pediatr Diabetes 2:170–174CrossRefPubMed Ludvigsson J, Ludvigsson M, Sepa A (2001) Screening for prediabetes in the general child population: maternal attitude to participation. Pediatr Diabetes 2:170–174CrossRefPubMed
19.
go back to reference Wahlberg J, Vaarala O, Ludvigsson J (2011) Asthma and allergic symptoms and type 1 diabetes-related autoantibodies in 2.5-yr-old children. Pediatr Diabetes 12:604–610CrossRefPubMed Wahlberg J, Vaarala O, Ludvigsson J (2011) Asthma and allergic symptoms and type 1 diabetes-related autoantibodies in 2.5-yr-old children. Pediatr Diabetes 12:604–610CrossRefPubMed
20.
go back to reference Williams AJ, Bingley PJ, Bonifacio E, Palmer JP, Gale EA (1997) A novel micro-assay for insulin autoantibodies. J Autoimmun 10:473–478CrossRefPubMed Williams AJ, Bingley PJ, Bonifacio E, Palmer JP, Gale EA (1997) A novel micro-assay for insulin autoantibodies. J Autoimmun 10:473–478CrossRefPubMed
21.
go back to reference Holmberg H, Vaarala O, Sadauskaite-Kuehne V, Ilonen J, Padaiga Z, Ludvigsson J (2006) Higher prevalence of autoantibodies to insulin and GAD65 in Swedish compared to Lithuanian children with type 1 diabetes. Diabetes Res Clin Pract 72:308–314CrossRefPubMed Holmberg H, Vaarala O, Sadauskaite-Kuehne V, Ilonen J, Padaiga Z, Ludvigsson J (2006) Higher prevalence of autoantibodies to insulin and GAD65 in Swedish compared to Lithuanian children with type 1 diabetes. Diabetes Res Clin Pract 72:308–314CrossRefPubMed
22.
go back to reference Vaziri-Sani F, Delli AJ, Elding-Larsson H et al (2011) A novel triple mix radiobinding assay for the three ZnT8 (ZnT8-RWQ) autoantibody variants in children with newly diagnosed diabetes. J Immunol Methods 371:25–37CrossRefPubMedPubMedCentral Vaziri-Sani F, Delli AJ, Elding-Larsson H et al (2011) A novel triple mix radiobinding assay for the three ZnT8 (ZnT8-RWQ) autoantibody variants in children with newly diagnosed diabetes. J Immunol Methods 371:25–37CrossRefPubMedPubMedCentral
23.
go back to reference Holmberg H, Wahlberg J, Vaarala O, Ludvigsson J (2007) Short duration of breast-feeding as a risk-factor for beta-cell autoantibodies in 5-year-old children from the general population. Br J Nutr 97:111–116CrossRefPubMed Holmberg H, Wahlberg J, Vaarala O, Ludvigsson J (2007) Short duration of breast-feeding as a risk-factor for beta-cell autoantibodies in 5-year-old children from the general population. Br J Nutr 97:111–116CrossRefPubMed
24.
go back to reference Hermann R, Turpeinen H, Laine AP et al (2003) HLA DR-DQ-encoded genetic determinants of childhood-onset type 1 diabetes in Finland: an analysis of 622 nuclear families. Tissue Antigens 62:162–169CrossRefPubMed Hermann R, Turpeinen H, Laine AP et al (2003) HLA DR-DQ-encoded genetic determinants of childhood-onset type 1 diabetes in Finland: an analysis of 622 nuclear families. Tissue Antigens 62:162–169CrossRefPubMed
25.
go back to reference Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460–468CrossRefPubMed Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460–468CrossRefPubMed
26.
go back to reference Trigwell SM, Radford PM, Page SR et al (2001) Islet glutamic acid decarboxylase modified by reactive oxygen species is recognized by antibodies from patients with type 1 diabetes mellitus. Clin Exp Immunol 126:242–249CrossRefPubMedPubMedCentral Trigwell SM, Radford PM, Page SR et al (2001) Islet glutamic acid decarboxylase modified by reactive oxygen species is recognized by antibodies from patients with type 1 diabetes mellitus. Clin Exp Immunol 126:242–249CrossRefPubMedPubMedCentral
27.
go back to reference Wiles TA, Delong T, Baker RL et al (2017) An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse. J Autoimmun 78:11–18CrossRefPubMed Wiles TA, Delong T, Baker RL et al (2017) An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse. J Autoimmun 78:11–18CrossRefPubMed
28.
go back to reference Rizzo P, Pitocco D, Zaccardi F et al (2017) Autoantibodies to post-translationally modified type I and II collagen in Charcot neuroarthropathy in subjects with type 2 diabetes mellitus. Diabetes Metab Res Rev 33:1–6CrossRef Rizzo P, Pitocco D, Zaccardi F et al (2017) Autoantibodies to post-translationally modified type I and II collagen in Charcot neuroarthropathy in subjects with type 2 diabetes mellitus. Diabetes Metab Res Rev 33:1–6CrossRef
29.
go back to reference Kaido T, Yebra M, Cirulli V, Montgomery AM (2004) Regulation of human β-cell adhesion, motility, and insulin secretion by collagen IV and its receptor α1β1. J Biol Chem 279:53762–53769CrossRefPubMed Kaido T, Yebra M, Cirulli V, Montgomery AM (2004) Regulation of human β-cell adhesion, motility, and insulin secretion by collagen IV and its receptor α1β1. J Biol Chem 279:53762–53769CrossRefPubMed
30.
go back to reference Triolo TM, Armstrong TK, McFann K et al (2011) Additional autoimmune disease found in 33% of patients at type 1 diabetes onset. Diabetes Care 34:1211–1213CrossRefPubMedPubMedCentral Triolo TM, Armstrong TK, McFann K et al (2011) Additional autoimmune disease found in 33% of patients at type 1 diabetes onset. Diabetes Care 34:1211–1213CrossRefPubMedPubMedCentral
31.
go back to reference Nakamura M, Yamazaki I, Nakagawa H, Ohtaki S, Ui N (1984) Iodination and oxidation of thyroglobulin catalyzed by thyroid peroxidase. J Biol Chem 259:359–364PubMed Nakamura M, Yamazaki I, Nakagawa H, Ohtaki S, Ui N (1984) Iodination and oxidation of thyroglobulin catalyzed by thyroid peroxidase. J Biol Chem 259:359–364PubMed
32.
go back to reference Orban T, Sosenko JM, Cuthbertson D et al (2009) Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 32:2269–2274CrossRefPubMedPubMedCentral Orban T, Sosenko JM, Cuthbertson D et al (2009) Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 32:2269–2274CrossRefPubMedPubMedCentral
33.
go back to reference Insel RA, Dunne JL, Atkinson MA et al (2015) Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38:1964–1974CrossRefPubMedPubMedCentral Insel RA, Dunne JL, Atkinson MA et al (2015) Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38:1964–1974CrossRefPubMedPubMedCentral
Metadata
Title
Antibodies to post-translationally modified insulin as a novel biomarker for prediction of type 1 diabetes in children
Authors
Rocky Strollo
Chiara Vinci
Nicola Napoli
Paolo Pozzilli
Johnny Ludvigsson
Ahuva Nissim
Publication date
01-08-2017
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 8/2017
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4296-1

Other articles of this Issue 8/2017

Diabetologia 8/2017 Go to the issue

Up front

Up front

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.